We are live on ! Find out more
NRXPW

NRX Pharmaceuticals Warrant
NRXPW

Delisted

NRXPW was delisted on the 22nd of May, 2026.

Back to rankings

17 hedge funds and large institutions have $458K invested in NRX Pharmaceuticals Warrant in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% less funds holding

Funds holding: 19 → 17 (-2)

31% less capital invested

Capital invested by funds: $663K → $458K (-$205K)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
17
Holders Change
-2
Holders Change %
-10.53%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
3
Closed
1
Calls
$14K
Puts
–
Net Calls
+$14K
Net Calls Change
+$14K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$60
2
CAC
Cowen and Company
New York
+$12

Top Sellers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
-$12.2K
2
BI
Bulldog Investors
New Jersey
-$1.97K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.16K
4
PAMP
Polar Asset Management Partners
Ontario, Canada
-$1.04K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$368K – – –
PAMP
2
Polar Asset Management Partners
Ontario, Canada
$24K -$1.04K -8,600 -2%
Hudson Bay Capital Management
3
Hudson Bay Capital Management
Connecticut
$13K – – –
VAS
4
VR Advisory Services
Cayman Islands
$10K – – –
RCM
5
Rivernorth Capital Management
Florida
$8K – – –
AA
6
AQR Arbitrage
Connecticut
$6K – – –
6CM
7
683 Capital Management
New York
$5K – – –
PC
8
Periscope Capital
Ontario, Canada
$5K – – –
YCM
9
Yakira Capital Management
Connecticut
$5K – – –
GCL
10
Glazer Capital LLC
New York
$4K – – –
CAC
11
Cowen and Company
New York
$4K +$12 +100 +0.2%
BI
12
Bulldog Investors
New Jersey
$3K -$1.97K -16,308 -23%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$1K -$1.16K -9,610 -31%
LIM
14
Longfellow Investment Management
Massachusetts
$1K – – –
Walleye Trading
15
Walleye Trading
New York
$1K – – –
KPF
16
K2 Principal Fund
Ontario, Canada
– -$12.2K -101,200 Closed
UBS Group
17
UBS Group
Switzerland
– +$60 +500 +9%

NRXPW Hedge Fund Activity: Q1 2020 in Review

17 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q1 2020, worth a combined $458K — down 31% from $663K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of NRXPW and 0 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $60. The largest seller was K2 Principal Fund, exiting entirely with an estimated $12.2K sold.

  • 17 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q1 2020, down from 19 in Q4 2019.
  • Funds reported $458K of NRX Pharmaceuticals Warrant stock for Q1 2020, down 31% quarter-over-quarter.
  • 0 funds opened new NRX Pharmaceuticals Warrant positions in Q1 2020 and 1 closed out, a net change of -1 holder.
  • The largest NRX Pharmaceuticals Warrant buyer in Q1 2020 was UBS Group, an estimated $60 added.
  • The largest NRX Pharmaceuticals Warrant seller in Q1 2020 was K2 Principal Fund, an estimated $12.2K sold.

Based on aggregated 13F filings for Q1 2020.